We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300595:SZSEOvctek China, Inc. Class A Analysis

Data as of 2026-05-30 - not real-time

CN¥12.08

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Autek China is trading well below its 20‑day and 50‑day moving averages, with price also under the 200‑day average, indicating a sustained bearish trend. The Relative Strength Index sits deep in oversold territory, while the MACD histogram remains negative, reinforcing short‑term downside pressure. Volume is on a downtrend, which often precedes further price weakness, and the stock’s beta is low, suggesting limited correlation with broader market moves. However, the discounted cash flow model points to a substantial upside potential, and the dividend yield, though modest, is supported by a strong cash balance and manageable free cash flow generation. Fundamentally, the company maintains healthy gross and operating margins, a solid return on equity, and a reasonable payout ratio, despite recent revenue contraction and a modest debt load.
Given the bearish technical signals but attractive valuation and dividend sustainability, the near‑term outlook remains cautious, while the medium‑ to long‑term perspective is more positive as the market may re‑price the stock to reflect its intrinsic value and the growing demand for eye‑care products in China.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below key moving averages
  • Oversold RSI suggesting limited upside in the immediate term
  • Decreasing trading volume indicating weak buying interest

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF indicates significant upside relative to current price
  • Sustainable dividend with strong cash generation
  • Solid profitability margins and low beta reducing market volatility exposure

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑run growth potential in China's eye‑care market
  • Consistent cash flow and manageable debt supporting financial stability
  • Undervaluation relative to industry peers and attractive dividend yield

Key Metrics & Analysis

Financial Health

Revenue Growth-3.90%
Profit Margin25.26%
P/E Ratio23.2
ROE9.83%
ROA5.93%
Debt/Equity3.98
P/B Ratio2.1
Op. Cash FlowCN¥681.3M
Free Cash FlowCN¥708.6M
Industry P/E27.6

Technical Analysis

TrendBearish
RSI24.8
SupportCN¥11.76
ResistanceCN¥15.18
MA 20CN¥13.29
MA 50CN¥13.92
MA 200CN¥15.92
MACDBearish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair ValueCN¥12.88
Target PriceCN¥16.28
Upside/Downside34.80%
GradeUndervalued
TypeValue
Dividend Yield1.56%

Risk Assessment

Beta0.19
Volatility20.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.